De ziekte van Behçet en de mogelijkheden van moderne tumornecrosisfactor-remmende medicatie

Translated title of the contribution: Behçet's disease and the possibilities of modern tumour necrosis factor inhibiting medication

J A M van Laar, A Jamnitski, G S Baarsma, P L A van Daele, P M van Hagen

Research output: Contribution to journalLetterpeer-review

Abstract

A 25-year-old woman was admitted after having had a fever for one month, headache, nausea, vomiting, dysarthria and right-sided hemiparesis. A 35-year-old man was admitted because of severe loss of vision and a history of focal retinochoroiditis. Both were suffering from Behçet's disease. Behçet's disease can present with systemic symptoms that might be related to aberrant T-cell functions. It is treated with a variety of immunoregulatory drugs. Recently, treatment with tumour necrosis factor (TNF) alpha-inhibiting molecular designed drugs such as infliximab or etanercept has improved the therapeutic prospective of Behçet patients. Both of the patients described above developed refractory disease and responded to treatment with these new drugs.

Translated title of the contributionBehçet's disease and the possibilities of modern tumour necrosis factor inhibiting medication
Original languageDutch
Pages (from-to)705-9
Number of pages5
JournalNederlands Tijdschrift voor Geneeskunde
Volume150
Issue number13
Publication statusPublished - 1 Apr 2006

Fingerprint

Dive into the research topics of 'Behçet's disease and the possibilities of modern tumour necrosis factor inhibiting medication'. Together they form a unique fingerprint.

Cite this